One of the world’s most prestigious eye hospitals and ophthalmology training excellence, Moorfields in London, is poised to release further data on the success of its paramedical intravitreal (IVT) injection training programme and practice.
The new data will be published shortly and then released publicly, said Adam Mapani, Moorfields’ first ophthalmology nurse consultant. “It’s been very successful. When the injections were first made available, waiting time was something like eight weeks and now with nurses’ involvement, it’s about two weeks… and the safety outcomes have been absolutely amazing… (with) a lower risk of endophthalmitis compared with doctor-led injections.”
The Moorfields’ IVT programme
Moorfields started training nurses and allied health professionals to give anti-vascular endothelial growth factor (anti-VEGF) injections in 2012 after identifying they had a serious and growing supply and demand problem.
The success of anti-VEGF agents in staving off blindness from wet age-related macular degeneration (AMD) has created unprecedented demand for injections. The problem is compounded by an aging population and anti-VEGF agents being successfully indicated for other conditions, such as diabetic macular oedema and retinal vein occlusions. Thus, the decision to train other staff to give IVT injections had the full support of the Moorfields Eye Hospital NHS Foundation Trust board and the medical director at the time, said Tracy Luckett, Moorfields director of nursing and allied health professionals.







